The Goldman Sachs Group Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00

Viridian Therapeutics (NASDAQ:VRDN) had its target price reduced by The Goldman Sachs Group from $41.00 to $36.00 in a research report released on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently issued reports on VRDN. Truist Financial dropped their price objective on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Evercore restated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wall Street Zen cut Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Wells Fargo & Company cut their price target on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, Wedbush reduced their price target on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $39.21.

Viridian Therapeutics Stock Down 1.6%

Shares of Viridian Therapeutics stock opened at $18.84 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $34.29. The firm’s 50-day moving average is $28.63 and its two-hundred day moving average is $27.77. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -5.73 and a beta of 1.16.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $15.75 million. As a group, research analysts expect that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Perceptive Advisors LLC lifted its position in Viridian Therapeutics by 108.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter. Morgan Stanley grew its holdings in Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after purchasing an additional 1,546,284 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Viridian Therapeutics during the fourth quarter worth $46,680,000. Vanguard Group Inc. increased its position in shares of Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP lifted its holdings in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter.

Trending Headlines about Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Topline REVEAL-1 Phase III results reported clinical activity for elegrobart — supports the drug’s efficacy and preserves an approval/commercial pathway, which is a material long-term positive for VRDN. Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
• Positive Sentiment: Some analysts remain constructive on longer-term upside: HC Wainwright maintains a Buy and has modeled recovery into FY2029–2030 (including a FY2030 EPS projection), reflecting belief in commercial potential beyond near-term noise. (Market commentary / analyst note summaries)
• Neutral Sentiment: Short-term trading has been volatile — the stock saw large swings on volume as the market digested nuanced efficacy/market-position takeaways; that raises short-term uncertainty but also increases liquidity for active traders. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
• Negative Sentiment: Market reaction included a sharp pre-market drop (reported ~41% at one point) as investors judged the results insufficiently dominant versus competitors and priced in execution/market-share risk. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
• Negative Sentiment: Several firms lowered expectations/targets after the readout: Goldman cut its price target, Wells Fargo trimmed its target to $20, and other notes signaled more cautious near-term forecasts — increasing near-term downside risk from analyst-driven flows. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00 Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
• Negative Sentiment: Critical takes emphasize that REVEAL-1 returned clinically meaningful but not clearly market-dominant data, which may limit peak sales vs. competitors and lengthen the commercialization ramp — a negative for near- to medium-term valuation. Viridian’s REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.